PEP-Therapy

📍 Paris, France🗓 Founded 2014👥 13 employees💰 Last funded Jul 2021
Biotechnology Research🌐 pep-therapy.com
Website LinkedIn
PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
3
Total investors
1
Early stage
0
Mid stage
2
Late stage
2014
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
2
Italy
1
Investor activity2015–2021 · investors recorded per year
2015120212
Recent (last 2y)Earlier
Frequently asked questions
Who invested in PEP-Therapy?
PEP-Therapy has 3 investors on record on gritt.io, including 1 early-stage backers and 2 late-stage investors.
When did PEP-Therapy last raise funding?
The most recent investment in PEP-Therapy recorded on gritt.io was in July 2021.
When was PEP-Therapy founded?
PEP-Therapy was founded in 2014.
What industry is PEP-Therapy in?
PEP-Therapy operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PEP-Therapy based?
PEP-Therapy is headquartered in Paris, France.